Lead Product(s): RZL 012
Therapeutic Area: Rare Diseases and Disorders Product Name: RZL 012
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: $74.0 million Upfront Cash: $27.0 million
Deal Type: Licensing Agreement September 17, 2020
RZL-012 is an injectable drug product indicated for aesthetic treatment of adults having moderate to significant submental fullness. Under the terms of the agreement, Raziel Therapeutics will receive potential payments between now and marketing approval in the Territory.